ASP Isotopes, Inc. (ASPI) AI Stock Analysis

• Market Cap: $946.21M
• Dividend Yield: N/A
• Average Volume (3M): 9.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: 99.57%
• EPS Growth: -126.31%
• Country: US
• Employees: 136
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): -0.64
• Shares Outstanding: 93,406,630
• 10 Day Avg. Volume: 7,874,412
• 30 Day Avg. Volume: 9,424,972
• PEG Ratio: -0.27
• Price to Book (P/B): 5.27
• Price to Sales (P/S): 60.85
• P/FCF Ratio: -8.99
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 68.01
• Enterprise Value/Gross Profit: 173.23
• Enterprise Value/Ebitda: -3.15
• 1Y Price Target: $13.00
• Price Target Upside: 28.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 49 Neutral
• Price Target: $10.00 ▼(-1.28% Downside)

ASP Isotopes, Inc. receives a score of 49, reflecting its mixed financial performance and technical analysis. The company's strong cash position and expansion plans are positive, but ongoing profitability challenges and high short interest pose significant risks. The lack of clear financial guidance adds uncertainty to its future prospects.

Positive Factors

Revenue Growth

The company has demonstrated strong revenue growth, which indicates expanding market reach and product adoption, crucial for long-term success.

Expansion Plans

Expansion into new facilities suggests strategic growth and increased production capacity, which can enhance market position and revenue streams.

Strategic Acquisition

The acquisition enhances vertical integration in the nuclear fuel cycle, potentially reducing costs and improving operational efficiency.

Negative Factors

Profitability Challenges

Ongoing profitability issues indicate high operational costs, which could hinder long-term financial health and investment capacity.

Negative Cash Flow

Negative cash flow reflects challenges in generating cash from operations, potentially impacting the ability to fund future growth initiatives.

Regulatory Delays

Delays in regulatory approvals can postpone expansion plans and revenue generation, affecting long-term strategic goals.

ASP Isotopes, Inc. Business Overview & Revenue Model

Company Description

ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.

How the Company Makes Money

ASP Isotopes, Inc. generates revenue through multiple streams, including the sale of isotopes to hospitals and medical facilities for use in imaging and therapeutic procedures. The company also earns income from contracts with research institutions and universities that require isotopes for experimental purposes. Additionally, ASPI partners with industrial firms for the use of isotopes in various applications, such as quality control and testing. Significant revenue is derived from long-term contracts and agreements that ensure a steady supply of isotopes, while ongoing research and development initiatives allow the company to innovate and expand its product offerings, further contributing to its profitability.

ASP Isotopes, Inc. Financial Statement Overview

Summary

ASP Isotopes, Inc. shows significant revenue growth but faces ongoing challenges with profitability and cash flow generation. The balance sheet is moderately leveraged with a strong cash position, yet profitability issues and negative cash flows highlight potential risks.

Income Statement

ASP Isotopes, Inc. has struggled with profitability as evidenced by persistently negative net income and EBIT across multiple years. The gross profit margin for the latest annual report is 38.6%, but the net profit margin is severely negative at -847.4%, indicating significant costs and expenses relative to revenue. There is, however, a significant increase in total revenue from 2023 to 2024, but given the high losses, revenue growth has not yet translated into profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.79, suggesting some reliance on debt for financing, but not excessively so. Equity represents about 50.7% of total assets, indicating a balanced capital structure. The cash position is strong with cash and equivalents exceeding total debt, providing a cushion for financial obligations. However, the persistently negative net income raises concerns about long-term equity value.

Cash Flow

ASP Isotopes, Inc. is experiencing negative operating and free cash flows, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is negative, aligning with the ongoing losses. Free cash flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures, which could impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.58M	4.14M	433.03K	0.00	0.00
Gross Profit	1.80M	1.60M	138.97K	-72.57K	-19.38K
EBITDA	-98.78M	-31.58M	-16.14M	-4.87M	-2.59M
Net Income	-99.96M	-32.33M	-16.29M	-4.79M	-2.61M
Balance Sheet
Total Assets	135.91M	94.35M	30.19M	12.50M	7.14M
Cash, Cash Equivalents and Short-Term Investments	67.68M	61.89M	7.91M	2.39M	2.95M
Total Debt	101.69M	37.75M	2.14M	822.20K	926.60K
Total Liabilities	107.60M	43.18M	11.36M	2.68M	1.14M
Stockholders Equity	25.23M	47.90M	16.30M	9.82M	6.00M
Cash Flow
Free Cash Flow	-31.28M	-28.07M	-7.74M	-7.41M	-3.57M
Operating Cash Flow	-19.67M	-16.70M	-5.41M	-2.94M	-577.69K
Investing Cash Flow	-42.42M	-11.37M	-2.45M	-4.47M	-2.99M
Financing Cash Flow	100.87M	82.53M	13.39M	6.64M	6.50M

ASP Isotopes, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASPI, the sentiment is Negative. The current price of 10.13 is below the 20-day moving average (MA) of 10.36, above the 50-day MA of 9.81, and above the 200-day MA of 7.50, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 55.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASPI.

ASP Isotopes, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASIX	―	$499.03M	6.55	9.85%	3.44%	1.31%	796.76%
Sector *	―	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
LXU	―	$607.21M	-796.23	-0.13%	―	12.49%	95.48%
RYAM	―	$465.66M	―	-81.36%	―	-4.90%	-458.80%
ASPI	―	$946.21M	―	-551.61%	―	99.57%	-126.31%
TROX	―	$554.84M	―	-14.11%	12.14%	0.20%	-292.54%
BAK	―	$1.04B	-0.97	―	―	-3.33%	44.37%

ASP Isotopes, Inc. Corporate Events

ASP Isotopes CEO Takes Temporary Leave for Health

On October 1, 2025, ASP Isotopes Inc. announced that Paul Mann, the founder, Chairman, and CEO, took a temporary leave of absence from his CEO duties for health reasons. In his absence, Robert Ainscow, the Chief Operating Officer, was appointed as Interim CEO while continuing his current duties. Mann will remain as Executive Chairman, focusing on the company’s leadership and strategic direction alongside Ainscow and the Board. The transition is expected to maintain the company’s operational stability and ensure continued communication with industry partners and stakeholders.

The most recent analyst rating on (ASPI) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.

ASP Isotopes’ Subsidiary Acquires Controlling Interest in SKBL

On August 29, 2025, Quantum Leap Energy LLC (QLE), a subsidiary of ASP Isotopes Inc., acquired a controlling interest in Skyline Builders Group Holding Limited (SKBL), a company listed on Nasdaq. This acquisition is part of QLE’s strategy to secure critical materials supply chains essential for U.S. security and QLE’s growth. The acquisition involved a purchase agreement with Supreme Development Holdings, the previous controlling shareholder, and a private placement that raised $17,775,000. This transaction allowed QLE to gain 79.14% of the voting power in SKBL, significantly enhancing its control and influence over the company.

The most recent analyst rating on (ASPI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.

ASP Isotopes Extends Deadline for Renergen Acquisition

On September 15, 2025, ASP Isotopes Inc. extended the deadline for fulfilling conditions related to its acquisition offer for Renergen Limited, a South African company. The extension, moving the longstop date to November 28, 2025, allows more time to secure necessary regulatory approvals and third-party consents, crucial for completing the acquisition under the South African legal framework.

The most recent analyst rating on (ASPI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.

ASP Isotopes Expands Board with New Appointment

On September 6, 2025, ASP Isotopes Inc. expanded its Board of Directors to seven members, appointing Ralph L. Hunter as a Class II director, effective September 8, 2025. Mr. Hunter, with over 35 years of experience in the nuclear sector, is expected to bring valuable expertise to the company, enhancing its strategic positioning in the industry.

The most recent analyst rating on (ASPI) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.

ASP Isotopes Plans Johannesburg Stock Exchange Listing

ASP Isotopes Inc. announced a corporate access event for South African investors on August 26, 2025, ahead of its secondary listing on the Johannesburg Stock Exchange, which is set to commence on August 27, 2025. The company is making significant strides in its isotope enrichment operations, with commercial production of Silicon-28 and Ytterbium-176 already underway and plans to expand its capabilities for other isotopes. Despite some delays in transitioning to semi-continuous processing for Ytterbium-176 and regulatory inspections affecting Carbon-12 production, the company is poised to enhance its production capacity and meet growing demand. Additionally, ASP Isotopes is preparing to spin out its Quantum Leap Enrichment subsidiary and finalize the acquisition of Renergen in the latter half of 2025.

The most recent analyst rating on (ASPI) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on ASP Isotopes, Inc. stock, see the ASPI Stock Forecast page.